Company Interview / CurveBeam AI's strategic partnership in China

Key Points:

CurveBeam AI achieves five US device orders and $2.4 million in receipts in December quarter Secured a $10 million strategic investment at five times current share value Plans expansion into China with local manufacturing and distribution Proprietary technology streamlines orthopaedic imaging and diagnosis, enhanced by AI

CurveBeam AI reports strong momentum in the December quarter, with chief executive Greg Brown highlighting five device purchase orders from the US and customer receipts of $2.4 million, reflecting a 75% increase from the previous quarter. The company specialises in point-of-care medical imaging equipment and AI-driven assessment solutions, specifically designed for orthopaedic use. Brown points to Europe currently being in a holding pattern due to pending reimbursement decisions, but expects international contributions to rise when these are finalised.

Brown outlines a significant $10 million investment from a strategic partner, representing a 5% stake at $0.40 per share—five times the current trading price. This deal not only enhances distribution for the US market but also supports manufacturing expansion for Asia and beyond. Brown emphasises the successful achievement of the first milestone in this agreement, with the corresponding cash expected to be released in Australia after regulatory approval.

On the technology front, Brown describes CurveBeam AI’s unique approach, enabling orthopaedic surgeons to conduct imaging and diagnosis in a single visit, including bone density analysis and advanced AI assessments. The company is also executing a push into China, facilitated by agreements for local manufacturing and distribution, aiming to access the country’s extensive hospital network and broader Southeast Asian and South American markets.